Immune complexes from SLE sera induce IL10 production from normal peripheral blood mononuclear cells by an FcgammaRII dependent mechanism: implications for a possible vicious cycle maintaining B cell hyperactivity in SLE
J Rönnelid, A Tejde, L Mathsson, K Nilsson-Ekdahl, B Nilsson, J Rönnelid, A Tejde, L Mathsson, K Nilsson-Ekdahl, B Nilsson
Abstract
Background: Raised interleukin (IL)6 and IL10 levels are thought to contribute to the pathogenesis of systemic lupus erythematosus (SLE) by enhancing autoantibody production and immune complex (IC) formation. These immune complexes can then stimulate cellular reactions through Fc and complement receptors.
Objective: To investigate whether circulating SLE ICs stimulate type 2 cytokine production.
Methods: Twenty serum samples from patients with active SLE were compared with sera from 18 healthy controls. Sera and polyethylene glycol (PEG) precipitates from sera were added to peripheral blood mononuclear cell (PBMC) cultures, and the production of IL10 and IL6 was investigated by enzyme linked immunospot assay (ELISPOT) and enzyme linked immunosorbent assay (ELISA). Fc gamma receptor (FcgammaR) antibodies were used in blocking experiments, and flow cytometry was used to assess the correlation between monocyte FcgammaR expression and IC-induced cytokine production.
Results: Ten per cent dilutions of the SLE sera induced a significantly increased number of IL10-producing cells in comparison with control sera (median, 11.75 v 1.25 spot forming cells/50 000 PBMC; p<0.0001). PEG precipitates from SLE sera also induced significantly increased levels of IL10 (p=0.016) and IL6 (p=0.042) in comparison with control PEG precipitates. IL10 production induced by SLE PEG precipitates or by artificial ICs could be blocked by anti-FcgammaRII antibodies, and the FcgammaRII expression on CD14+ monocytes correlated with the IC-induced production of IL10 and IL6.
Conclusions: SLE sera stimulate IL10 and IL6 production from PBMC, and this effect is at least partly explained by precipitable ICs acting through FcgammaRII. This effect provides a possible mechanism for the enhanced production of IL10 in SLE, whereby B cell activation, antibody production, IC stimulated monocytes/macrophages, and type 2 cytokines create a vicious cycle that may help to maintain B cell hyperactivity in SLE.
Figures
References
- Clin Exp Rheumatol. 2000 Sep-Oct;18(5):565-70
- Arthritis Res. 2000;2(1):75-84
- Trends Immunol. 2001 Aug;22(8):427-31
- Science. 2001 Nov 16;294(5546):1540-3
- J Interferon Cytokine Res. 2002 Mar;22(3):311-9
- Immunology. 1970 Dec;19(6):909-19
- Arthritis Rheum. 1982 Nov;25(11):1271-7
- J Immunol Methods. 1984 Aug 3;72(1):49-59
- J Immunol. 1993 Dec 15;151(12):6853-61
- Eur Cytokine Netw. 1993 Nov-Dec;4(6):421-7
- Scand J Immunol. 1994 Aug;40(2):243-50
- Arthritis Rheum. 1994 Nov;37(11):1647-55
- Lymphokine Cytokine Res. 1994 Aug;13(4):259-63
- J Exp Med. 1995 Mar 1;181(3):839-44
- J Immunol. 1995 Apr 1;154(7):3454-60
- J Clin Invest. 1995 Apr;95(4):1628-34
- Lupus. 1995 Oct;4(5):393-5
- Arthritis Rheum. 1996 Mar;39(3):379-85
- Eur J Immunol. 1996 Jun;26(6):1297-301
- Arch Immunol Ther Exp (Warsz). 1995;43(1):11-4
- J Clin Immunol. 1996 Jul;16(4):198-207
- J Clin Immunol. 1996 Sep;16(5):291-303
- Res Virol. 1996 Mar-Jun;147(2-3):103-8
- J Immunol Methods. 1997 Jan 15;200(1-2):17-26
- Clin Rheumatol. 1997 May;16(3):275-8
- Eur Cytokine Netw. 1997 Sep;8(3):281-6
- Scand J Immunol. 1997 Oct;46(4):406-12
- Eur J Immunol. 1997 Nov;27(11):2994-3000
- Clin Exp Rheumatol. 1998 May-Jun;16(3):283-8
- Arthritis Rheum. 1998 Jul;41(7):1181-9
- Immunogenetics. 1998 Aug;48(3):222-32
- Clin Exp Immunol. 1999 Jan;115(1):189-95
- Clin Immunol. 1999 Apr;91(1):6-16
- Arthritis Rheum. 1999 Aug;42(8):1649-54
- Arthritis Rheum. 1999 Sep;42(9):1828-32
- Eur Cytokine Netw. 1999 Dec;10(4):509-14
Source: PubMed